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ABSTRACT 
 
Glial cell line-derived neurotrophic factor (GDNF) is the prototypical member of 
a family of growth factors that are indispensable in nervous system 
development and maintenance. GDNF signals by binding to a multi-component 
receptor complex comprised of the ligand-binding subunit GFR!1 and the 
signaling subunit RET or NCAM. While initial interest in GDNF was merely 
focused on its potential therapeutic effects in Parkinson’s disease, it has rapidly 
become evident that the mechanisms by which GDNF and its receptors 
regulate diverse physiological events are incomplete. Thus, we have 
demonstrated new insights into the control of neuronal survival, migration, and 
outgrowth by GDNF and its receptors.  
 
To begin clarifing the complexity of GDNF signaling, we examined RET 
intracellular tyrosine residues which become phosphorylated upon receptor 
activation, and serve as docking sites for downstream signaling effectors. The 
functions of most of these phosphorylated tyrosine residues are still unknown. 
In paper I, we identified the protein-tyrosine phosphatase SHP2 as a novel 
direct interactor of RET and as the first effector known to bind to 
phosphorylated Tyr687. Furthermore, we found that activation of protein kinase 
A (PKA) by forskolin reduced the recruitment of SHP2 to RET, negatively 
affecting ligand-mediated neurite outgrowth. Together, these findings establish 
SHP2 as a novel positive regulator of RET function and reveal Tyr687 as a 
critical platform for integration of RET and PKA signals.   
 
To continue to understand GDNF signaling diversity, we examined RET 
signaling in a clinical context. Most patients with medullary thyroid carcinoma 
(MTC) and type 2A multiple endrocrine neoplasia (MEN2A) exhibit cysteine 
residue mutations in the juxtamembrane region of RET which result in 
unexplained oncogenic activation. Thus, in paper II we identified and described 
the self-association determinants of the RET transmembrane (RET-TM) 
domain underlying such oncogenic activation by mutations found in these 
patients. We found that strong propensity for RET-TM self-association 
underlies - and may be required for – dimer formation and oncogenic activation 
by juxtamembrane cysteine mutations localized in close proximity to the 
plasma membrane in MTC and MEN2A syndromes. 
 
To further dissect the many facets of GDNF signaling, we alternatively 
investigated the functions of GDNF and GFR!1 independent of RET. GDNF 
promotes the differentiation and migration of GABAergic neuronal precursors 
from the medial ganglionic eminence (MGE). These functions are dependent 
on GFR!1, but are independent of the two known receptor partners RET and 
NCAM. In paper III, we revealed that soluble GFR!1 is able to promote 
GABAergic differentiation and migration, but requires endogenous GDNF 
production. Furthermore, we showed that MET signaling inhibition promoted 
the same physiological response as GDNF. Finally, we justified the existence 
of a novel transmembrane receptor for the GDNF/GFR!1 complex and 
uncovered an unexpected interplay between GDNF/GFR!1 and HGF/Met 
signaling in the early diversification of GABAergic MGE interneuron subtypes.  
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PROLOGUE 
 
Why did I study GDNF?  
My interest to focus my doctoral research on GDNF transpired after 
reading a report on a phase I clinical trial of Parkinson patients treated 
with GDNF (Gill 2003). This safety open-label trial, in which all five 
patients showed improvements in standard scores of movement and 
motor skills, inspired me to pursue hands-on fundamental research 
dissecting the intracellular pathways mediated by GDNF in neuronal 
survival, outgrowth, and differentiation. As I embarked on this 
research, Amgen, the company holding the patent for the clinical use 
of GDNF, decided to halt all future clinical trials after a review of the 
phase II trial. They reported that there was patient safety concerns as 
few patients clinically improved (even placebo controls) while other 
patients’ conditions severely worsened. Two participants in the study 
even developed neutralizing antibodies against GDNF. This was 
Amgen’s second clinical trial failure, after an initial double-blind safety 
trial showed extensive side effects suffered by patients treated with 
GDNF without any clinical improvement (Nutt 2003). Amgen sadly 
refused all patients, even Gill’s patients still under treatment, the right 
to continue taking GDNF to dampen their symptoms of Parkinson’s 
disease. Regrettably, this halt then lead to a lawsuit between both 
parties. Interestingly, post-mortem data of these clinical trials have 
shown that GDNF did not efficiently reach the target tissues – as 
GDNF cannot cross the blood-brain barrier. From this data emerged an 
important understanding of GDNF and drug delivery methods: GDNF 
must be delivered in a different manner to precisely reach target 
tissues, and deeper insights into the physiological neurotrophic 
activities of GDNF on human dopaminergic neurons were needed. As 
a result, Amgen decided to make their pre-clinical GDNF available to 
scientists to examine GDNF’s mechanisms of action. Our laboratory 
was a recipient of Amgen’s GDNF, which was not only used in my 
studies, but was more importantly the motivating foundation of my 
doctoral research.  
The results of my research endeavors are presented in this thesis.  
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INTRODUCTION  
 
GDNF FAMILY LIGANDS AND THEIR RECEPTORS 
Glial cell line-derived neurotrophic factor (GDNF) was first discovered 
in 1993 by scientists at the company Synergen in a screen to discover 
novel secreted neurotrophic factors enhancing survival of primary 
dopaminergic (DA) neurons isolated from rat embryonic midbrains (Lin 
1993). The protein was initially purified from conditioned media of the 
rat B49 glial cell line and characterized as a disulfide-linked 
homodimeric glycoprotein with neurotrophic activities specific to 
dopaminergic neurons (Lin 1994). Human GDNF cDNA encodes a 211 
amino acid residue prepropeptide precursor that is further processed 
by furin-type endopeptidases to yield a predicted 30 kDa mature 
homodimeric molecule formed by two identical 134 amino acid 
subunits (Lonka-Nevalaita 2010). The two monomers are associated in 
a head-to-tail orientation displaying anti-parallel left-right symmetry 
(Eigenbrot 1997). 
GDNF is the prototypical member of the GDNF family ligands (GFLs) 
that also include Neurturin (NRTN), Artemin (ARTN), and Persephin 
(PSPN) (Fig.1). NRTN was isolated from conditioned media of the 
Chinese hamster ovarian (CHO) cell line, as it displayed the ability to 
promote the survival of cultured sympathetic neurons from the superior 
cervical ganglion (SCG) (Kotzbauer 1996). PSPN was thereafter 
cloned by degenerate PCR (Milbrandt 1998) and ARTN was found by 
multiple database searches based on its homology to mature NRTN 
(Baloh 1998). The GFLs are distant members of the transforming 
growth factor-beta (TGF-") superfamily, which are characterized by a 
common three-dimensional fold containing a cysteine knot (Eketjall 
2004). GDNF shares only a 23% sequence similarity with TGF-" 
superfamily members and differs from them as it distinctly signals 
through a receptor tyrosine kinase instead of a serine/threonine kinase 
(Massague 1998, Saarma 2000).  
Although many growth factors bind directly to their receptor kinase, the 
GFLs are unique in that they must first bind to one of the four GDNF 
family receptor alphas (GFR!1#4) (Fig. 1). GFR!‘s are 
glycosylphosphatidylinositol (GPI)-anchored membrane proteins that 
were originally discovered by expression cloning and screening of 
GDNF binding proteins (Jing 1996, Treanor 1996). GFR! proteins can 
be cleaved by phospholipases and are functional in soluble form 
(Paratcha 2001). While GDNF preferentially binds to GFR!1, there is 
some promiscuity within the family as GDNF can also bind to both 
GFR!2 and GFR!4 (Fig. 1) (Airaksinen 2002, Sidorova 2010).  
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Figure 1: The GDNF family ligands and their respective GFR! 
receptors. Dashed lines represent known interactions while a full line 
represents the preferred binding receptor for each ligand. 
 
In order to signal across the cell membrane, the GDNF/GFR! complex 
must bind to a transmembrane receptor protein - either the receptor 
tyrosine kinase RET or the neural cell adhesion molecule NCAM 
(Durbec 1996, Trupp 1996, Paratcha 2003). These GFR! co-receptors 
are understood to determine both RET ligand binding specificity and to 
facilitate RET activation (Scott 2001). The current model argues for 
GDNF binding first to GFR!1 and subsequently to RET although some 
evidence argues in favor of GDNF binding to a preformed GFR!1/RET 
complex (Fig. 4) (Eketjall 1999, Cik 2000, Simi 2010). All four members 
of the GFLs signal through this multi-receptor complex comprised of 
the respective ligand, the corresponding GFR! co-receptor binding 
subunit, and finally the signaling subunit RET or NCAM.  
Both the GFR! co-receptor and the signaling receptor are linked as 
dimers, resulting in a 2:2:2 stoichiometric signaling receptor; although 
the tridimensional structure of this hetero-hexameric complex still 
awaits confirmation by high-resolution crystallization techniques 
(Leppanen 2004, Sjostrand 2007, Parkash 2009, Simi 2010). 
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GDNF, GFR!1 AND RET IN DEVELOPMENT 
Embryonic development: Findings from the knock-outs 
Studies using knock-out mice for GDNF, GFR!1, and RET have 
demonstrated the important roles that these molecules play in 
embryonic development. Most strikingly, Gdnf -/-, Gfra1 -/- and Ret -/- 
mice die perinatally due to kidney agenesis or severe dysgenesis and 
display a severe phenotype in the peripheral nervous system (PNS) 
(Schuchardt 1994, Moore 1996, Sanchez 1996, Cacalano 1998, 
Enomoto 1998). In the enteric nervous system (ENS), they have 
incomplete innervations or a total lack of enteric neurons in the small 
and large intestine. In the autonomic nervous system, both the 
parasympathetic and sympathetic nervous systems are severely 
affected due to the complete genetic ablation of Gdnf or its receptors. 
RET-deficient mice display impaired sympathetic neuron precursor 
migration and axonal growth (Durbec 1996; Enomoto 2001). GDNF 
knock-out animals have a 35% loss of superior cervical ganglion 
(SCG) neurons (Moore 1996). Interestingly, ablation of GFR!1 
expression does not affect sensory neuron numbers (Cacalano 1998, 
Enomoto 1998). The central nervous system (CNS) was essentially 
unaffected by the deletion of these proteins, with the exception of a 
22% loss of spinal motoneurons in the Gdnf and the Gfra1 null mice 
(Airaksinen 1999). For most researchers the lack of phenotype in the 
ventral midbrain was a major disappointment because it suggested 
that these proteins were not essential for the embryonic development 
of DA neurons in vivo. As a result, a deeper understanding of the 
temporal pattern of expression of GDNF and its receptors was 
required. 
 
Brain development: From primary cultures to conditional knock-
outs 
Since the early discovery of GDNF’s neurotrophic activities on primary 
midbrain dopaminergic neurons, other brain regions were 
subsequently investigated for expression of GDNF and its receptors. 
GDNF and GFR!1 were found to be strongly expressed in the 
olfactory bulb and in the olfactory neuroepithelium (Trupp 1997, 
Maroldt 2005). Within the olfactory bulb, GDNF was suggested to act 
as a diffusible chemoattractant to neuronal progenitors migrating along 
the rostral migratory stream that originated from the subventricular 
zone of the lateral ventricle in an NCAM-dependent manner (Paratcha 
2006). In primary hippocampal and cortical neurons, GDNF has been 
shown to promote axonal growth via binding to NCAM (Paratcha 2003, 
Nielsen 2009). In the hippocampus, a region devoid of RET 
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expression, GDNF in known to promote neuronal synapse formation 
through trans-homophilic binding between GFR!1 proteins expressed 
in both pre- and post-synaptic terminals (Ledda 2007). Due to the 
neonatal lethality of Gdnf, Gfra1, and Ret null mice, very little was 
understood about the physiological role of these proteins in postnatal 
brain development and adult plasticity until the advent of the GFLs 
conditional knock-out mice.  
Recent publications of conditional knock-out mice have expanded the 
current knowledge of the physiological roles that GDNF and its 
receptors play in vivo. This genetic technology relies on the ability of 
the Cre recombinase of bacteriophage P1 to catalyze the excision of 
the DNA flanked by loxP recognition sequences (Sauer 1988). In 
conditional knock-outs, spatially controlled gene deletion is obtained by 
breeding genetically modified mice carrying alleles of the gene of 
interest flanked by loxP sites together with mice expressing the Cre 
recombinase from the locus of specific genes expressed in the target 
tissue. Therefore, embryonic lethality can be rescued in these animals 
through genuine expression of GDNF and its receptors in 
tissues/organs essential for embryonic development (such as kidneys, 
ureter and enteric neurons) while gene expression in targeted tissue is 
ablated. In light of the reported dopaminotrophic activities by GDNF, 
the first tissue targeted by the conditional ablation of RET was the 
ventral mesencephalon, with a focus on the substantia nigra pars 
compacta (SNpc) and the ventral tangmental area (VTA) (Lin 1993, 
Stromberg 1993). Surprisingly, excision of RET in cells expressing the 
dopamine transporter DAT showed that RET was dispensable for the 
maintenance of DA neurons (Jain 2006). In contrast, another study 
found that Ret ablation caused progressive and late loss of DA 
neurons in the SNpc with severe degeneration of the nigrostratial DA 
terminals (Kramer 2007). In one year old mice, a significant 25% loss 
of tyrosine hydroxylase (TH) fibers was observed compared to age-
matched control mice; a result which increased further to 38% in two 
year old animals. Interestingly, both studies used the DAT-Cre mice to 
excise the floxed Ret allele. Although their results lead to different 
conclusions in aged mice, both studies concur that RET is dispensable 
for the development and early maturation of the DA nigrostriatal 
system. 
Scientists had long questioned GDNF’s physiological role in ventral 
mesencephalon development and maintenance; since both Gdnf and 
Gfra1 null mice suffer no DA nigrostriatal system deficits at birth 
(Moore 1996, Enomoto 1998, Baloh 2000). Instead of inactivating the 
gene of interest in the tissue of interest during embryogenesis, as was 
devised for both Ret conditional knock-outs, a different strategy was 
used for the deletion of the Gdnf conditional allele. A tamoxifen-
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inducible CRE recombinase (Esr1-Cre) with ubiquitous expression was 
employed to regulate temporal gene inactivation (Hayashi 2002, Vooijs 
2001). To obtain the conditional Gdnf mouse, heterozygous Gdnf mice 
were first crossed with Esr1-Cre mice, and their progeny was further 
crossed in the Gdnf F/+ floxed allele to obtain the desired Gdnf F/-;Esr1-
Cre genotype (Pascual 2008). The conditional Gdnf allele was excised 
in all cells of the body following tamoxifen injection in two month old 
animals; histological analysis was performed seven months later. 
Surprisingly, 60-70% of the dopaminergic neurons in the SN and the 
VTA were lost in these animals; a phenotype which was accentuated in 
the locus coeruleus with the absence of noradrenergic neurons 
(Pascual 2008). These results re-established GDNF’s critical role in the 
survival and maintenance of adult catecholaminergic neurons. 
Additionally, these results indicated that a loss of GDNF could be an 
important contributor in the pathophysiology of neurodegeneration 
observed in Parkinson disease (Ibanez 2008). 
 
Cortical interneuron development: GFR!1 in GABAergic 
specification? 
While the human cerebral cortex accounts for ~80% of the total volume 
of the brain, interneurons represent about 25% of all neurons in the 
cortex (Hendry 1987, Meinecke 1987, Swanson 1995). For proper 
network activity to be achieved, the cerebral cortex maintains a very 
tightly synchronized regulation by the coordinated actions of two types 
of neurons, excitatory glutamatergic projection neurons and inhibitory 
local-circuit GABAergic interneurons (Wonders 2006). These neurons 
are born in distinct proliferative zones of the cerebral cortex and 
migrate long distances to reach their final position within the network 
(Corbin 2001). Projection neurons are born in the cortical ventricular 
zone and migrate via radial migration into the cortical plate. On the 
other hand, GABAergic interneurons originate in the transient 
neurogenic zone of the subpallial telencephalon and migrate 
tangentially into the neocortex between embryonic day 12.5 (E12.5) 
and E15.5 in the mouse (Fig. 2) (Marin 2003, Levitt 2004). Cortical 
GABAergic interneuron neurogenesis has been shown to occur in both 
the medial (MGE) and the caudal ganglionic eminences (CGE); 
whereas the lateral (LGE) ganglionic eminence gives rise to 
interneurons destined to migrate through the rostral migratory stream 
(RMS) to the olfactory bulb (Anderson 1997, Wichterle 1999, Anderson 
2001, Nery 2002, Metin 2006). Cortical GABAergic interneurons make 
up a highly heteregenous cell population classified by their 
morphologies, electrophysiological properties, ion channels, 
neuropeptides, and calcium binding properties (Markram 2004).  
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Figure 2: Ganglionic eminences of the developing telencephalon in an 
E12.5 mouse embryo (A and B). Schematic delineating the medial, 
lateral, and caudal ganglionic eminence borders (MGE, LGE, CGE) are 
shown in panel C. Tangential migration route of GABAergic interneurons, 
born in the MGE and traveling to the Neocortex (NCx), is depicted in a 
coronal section of the mouse head (D). 
Many growth factors have been shown to be motogens for migrating 
interneurons from the MGE including: semaphorins, hepatocyte growth 
factor (HGF), neurotrophins, and neuregulin-1 (NG-1) (Marin 2001, 
Powell 2001, Polleux 2002, Flames 2004). Although combinatorial 
codes of transcription factors have been found to delineate different 
progenitor domains in the SVZ of the MGE, it remains unclear as to 
exactly how interneuron diversity is achieved (Flames 2007, Fogarty 
2007, Liodis 2007, Miyoshi 2007). 
GDNF was shown to promote differentiation and tangential migration of 
GABAergic cortical neurons isolated from the MGE (Pozas 2005). 
These GDNF functions are understood to be independent of the two 
known transmembrane receptors, RET and NCAM, but are dependent 
upon GFR!1. GFR!1 expression was detected in a subset of 
postmitotic GABAergic precursors located in the ventral MGE, whereas 
Gdnf mRNA was found in the MGE and in the neocortex. Very low 
levels of Ret mRNA were observed in the MGE, signifying that a 
different transmembrane receptor was used by GDNF in these cells 
(Pozas 2005). In a subsequent study, GFR!1 was further shown to be 
required for the correct allocation of parvalbumin (PV) expressing 
interneurons in the cortex, using a mutant mouse line that rescues the 
lethality of the Gfra1 null animals (Canty 2009). In these “cis-only” 
mice, Gfra1 cDNA is expressed under the Ret locus in order to ablate 
Gfra1 solely in cells that do not express RET (Enomoto 2004). Cis-only 
mice displayed a severe PV interneuron loss in discrete regions of the 
cortex, while other cortical regions remained unaffected by the loss of 
GFR!1. These results indicated that GFR!1 may guide the 
development of a subset of PV-expressing interneurons; and therefore 
may contribute to the diversification and later allocation of distinct 
cortical interneuron subtypes. 
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CONSTITUTIVE AND GDNF-MEDIATED RET SIGNALING 
 
RET: Structural features for signaling purposes 
RET (rearranged during transfection) was originally identified as a 
novel oncogene activated by DNA rearrangement using the murine 
NIH 3T3 cell line transfected with human lymphoma DNA (Takahashi 
1985, Tahira 1990). The Ret gene was subsequently cloned, 
containing 21 exons localized to chromosome 10, and was shown to 
encode a receptor tyrosine kinase (RTK) expressed in many tumor cell 
lines (Takahashi 1987). The RET extracellular domain (ECD) is 
comprised of four cadherin-like motifs containing a calcium binding site 
between the second and third cadherin-like domains (CLD, Fig. 3), 
which is followed by a cysteine-rich domain (CRD) of ~120 residues 
containing a highly conserved group of 14 cysteines adjacent to the 
transmembrane (TM) domain (Fig. 3) (Airaksinen 1999, Anders 2001). 
The RET TM domain spans from residue 636-657, however nothing 
was known of its potential role in functional regulation of RET outputs 
until the publication of our investigation presented in paper II. The RET 
intracellular domain (ICD) contains two tyrosine kinase (TK) 
subdomains separated by a kinase insert. Alternative splicing of 3’ 
sequences of exon 19 leads to three RET isoforms: RET9, RET51, and 
a rare RET43 (Myers 1995). RET9 (1072 amino acids) and RET51 
(1114 amino acids) diverge in their tail sequence downstream of 
glycine 1063 (Santoro 2004). The RET9 ICD contains 16 tyrosine (Y) 
residues but lacks Y1090 and Y1096, which are present in RET51. 
 
Figure 3: Schematic representation of RET structural domains. Amino acid 
residue numbers are allocated according to the human RET51 isoform. 
 
RET activation: Tyrosyl phosphorylation as a kick start 
RET activation is achieved by two means: either upon ligand/GFR! 
receptor complex interaction or when carrying a point mutation 
rendering dimeric RET to be constitutively active (Fig. 4) (Takahashi 
2001). Receptor dimerization promotes trans-phosphorylation of 
intracellular tyrosine residues which then serve as docking sites for 
various adaptor proteins containing either Src homology 2 (SH2) 
domains or phosphotyrosine binding domains (PTB) (Pawson 1995).  
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Figure 4: RET activation is 
achieved either by interaction 
with the GDNF/GFR!1 
complex (A) or by constitutive 
activation due to mutations in 
extracellular juxtamembrane 
cysteine residues shown in 
red (B). 
 
 
 
At least 14 of the 18 intracellular tyrosine residues have been found to 
be phosphorylated in human RET51; as identified by phosphopeptide 
mapping or mass spectrometry including: Y687, Y752, Y806, Y809, 
Y826, Y900, Y905, Y928, Y981, Y1015, Y1029, Y1062, Y1090, and 
Y1096 (Liu 1996, Kawamoto 2004, Knowles 2006). The tyrosines Y900 
and Y905 are both found within the kinase domain activation loop. 
Tyr905 has been shown to be required for full RET activation and 
downstream signaling (Coulpier 2002). Site-specific adaptor proteins 
have also been identified for some of these tyrosine residues such as: 
Tyr905, Tyr981, Tyr1015 and Tyr1096. When phophorylated, these become  
binding sites for Grb7/10, Src, PLC!, and Grb2, respectively (Pandey 
1996, Encinas 2004, Borrello 1996, Alberti 1998). While Tyr752 and 
Tyr826 can bind directly to the STAT3 transcription factor (Schuringa 
2001), Tyr1062 has been revealed as a multi-docking site for Shc, 
FRS2, IRS, and Dok (Fig. 5) (Arighi 1997, Kurokawa 2001, Melillo 
2001, Grimm 2001). Subsequently, Shc was found to recruit Grb2 
which further associates with Gab2 and SHP2; thereby arguing for a 
multi-protein scaffolding recruitment of phophorylated Y1062 (Besset 
2000). SHP2 is a protein-tyrosine phosphatase containing two SH2 
domains followed by a C-terminal phosphatase domain, and its most 
N-terminal SH2 domain has been shown to bind distinct phospho-Tyr 
residues in activated RTKs (Chan 2008). Germline mutations in Shp2 
lead to the Noonan and LEOPARD syndromes characterized by 
cardiac abnormalities and dysmorphic facial features (Tartaglia 2001). 
Tyr687 remained uncharacterized until our investigation decribed its 
significance which is presented in paper I. 
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RET intracellular pathways: Beyond neurotrophic survival 
Tyrosine Y1062 has often been conceptualized as the motor of RET 
activation, while the other tyrosine residues act more like signaling 
modulators of RET. Knock-in animals, carrying the silencing mutation 
of Y1062F, display a similar phenotype as RET null mutants 
demonstrating the importance of this residue in RET signaling during 
development (Jijiwa 2004, Jain 2006). In vitro, Tyr1062 activates various 
intracellular signaling pathways including: the PI3K/Akt, Ras/Erk, Jnk, 
and p38MAPK (Fig. 5). Downstream activation of these pathways 
consequentially leads to transcriptional induction by the CREB and NF-
$B transcription factors (Hayashi 2000). Extensive bodies of work have 
been devoted to correlate each signaling pathway to a specific 
biological response such as: proliferation, survival, migration, cell cycle 
progression, and neurite outgrowth (Gustin 2007). However, most 
tyrosines have revealed redundant physiological responses. For 
instance, the recruitment of Grb2 by Tyr1096 activates both the PI3K 
and the MAPK signaling pathways in a similar pattern to Y1062 
(Degl’Innocenti 2004, Jain 2006). Moreover, Serine S696 was shown 
to be phosphorylated by PKA promoting Rac-GEF activity through Jnk 
resulting in lamellipodia formation of neuroblatoma cell lines (Fukuda 
2002). Knock-in animals carrying a mutation of this serine residue into 
an alanine displayed a severe migratory defect in enteric neural crest 
cells thereby lacking enteric neurons in the distal colon (Asai 2006).  
 
 
 
 
 
 
 
 
 
 
Figure 5: Adaptor proteins known to bind to phosphorylated intracellular 
tyrosine residues of RET and their respective downstream signaling 
pathways. Note that that the juxtamembrane tyrosine 687 remains 
uncharacterized. 
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GDNF and RET in disease 
As described in the prologue, GDNF has been extensively studied for 
its neurotrophic function in support of nigrostriatal dopaminergic 
neurons in humans (Grondin 1998, Hurelbrink 2001). Extensive efforts 
on various animal models of amyotrophic lateral sclerosis (ALS), spinal 
cord injury, and cerebral ischemia have demonstrated the regenerative 
potential of GDNF on nerve degeneration (Mohajeri 1999, Wang 2002, 
Suzuki 2007, Cao 2003, Zhang 2009, Kilic 2003). 
Ret mutations however have been more commonly associated with 
human diseases. Receptor tyrosine kinases (RTKs) are key regulators 
of crucial cellular processes such as growth, differentiation, migration, 
proliferation, and apoptosis (Robinson 2000). Subtle changes in the 
regulation of RTK activity often result in aberrant signaling which is 
known to be critically involved in human cancers (Ullrich 1984, Zwick 
2001). RET is no exception in the RTK family. Single point mutations 
lead to the formation of active dimers, inducing constitutive activation 
of the tyrosine kinase and consequently generating oncongenic 
transforming potential (Asai 1995). These mutations are found in the 
RET extracellular domain (ECD) on cysteine residues C609, C611, 
C618, C620, C630 and C634 and result in a free unpaired cysteine 
able to form intermolecular disulphide bonds (Santoro 1995, Lai 2007).  
Gain-of-function dominant Ret mutations have been found in patients 
with types 2A and 2B multiple endocrine neoplasia (MEN) as well as 
and sporadic and inherited medullary thyroid carcinoma (respectively 
MTC, FMTC) (Manie 2001). MEN2A is characterized by MTC and 
pheochromocytomas; the clinical MEN2B phenotype also includes oral 
neuromas, ganglioneuromatosis, skeletal abnormalities, and is 
characterized by a mutation in the residues A883 or M918 (Donis-
Keller 1993, Mulligan 1993, Mulligan 1994). Loss-of-function mutations 
of the Ret allele have been found in Hirschsprung’s disease (HSCR), 
which is a congenital developmental condition characterized by 
incomplete innervations of the distal gut (Edery 1994, Kashuk 2005). 
Although they were not causal of HSCR, two germline Gdnf mutations 
leading to the P21S and the I211M residue substitutions have been 
reported (Salomon 1996, Martucciello 1998, Martucciello 2000). 
Approximately 90% of all HSCR cases are directly linked to a Ret gene 
mutation (Lantieri 2006). 
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AIMS  
 
The principal objective of this thesis was to explore the signaling 
mechanisms activated by GDNF that control critical cellular events 
such as: neuronal survival, growth, migration, and differentiation.  
Specifically: 
1. Evaluate the role of the juxtamembrane tyrosine residue 687 of 
RET in promoting neuronal survival and neurite outgrowth in SCG 
neurons. 
2. Determine the self-association mechanism of the RET 
transmembrane domain underlying oncongenic MEN2A mutations. 
3. Elucidate the role of GDNF and GFR!1 signaling in GABAergic 
differentiation and cell migration of cortical interneuron precursors 
of the medial ganglionic eminence. 
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COMMENTS ON MATERIALS AND METHODS  
 
The materials and methods used in this thesis have been described in 
the papers I-III. Please refer to the corresponding methods section of 
each paper for a detailed account. The following comments briefly 
characterize the experimental methodology for clarification. 
 
NEURONAL SURVIVAL 
 
In paper I, we studied the role of RET-mediated neuronal survival in 
sympathetic neurons isolated from superior cervical ganglia (SCG). 
Dissociated neurons were microporated with the RET plasmid of 
interest together with dsRed for subsequent visualization in an Axiovert 
200M inverted fluorescence microscope (Zeiss). After the first day in 
culture (DIV1), individual neurons were imaged and their precise 
spatial position was recorded in order to follow their daily survival using 
the OpenLab software (Improvision). Axonal fragmentation followed by 
cell soma collapse was evaluated to quantify cell death (Fig. 6). 
Subsequent TUNEL staining confirmed apoptotic cell death. 
 
 
Figure 6: SCG neurons expressing specific RET constructs together 
with dsRed following 2 and 3 days in culture, respectively. Axonal 
fragmentation is observed in panel B’. 
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NEURITE OUTGROWTH 
RET-mediated neurite outgrowth in sympathetic neurons 
In paper I, we examined the role of tyrosine residue Y687 on neurite 
outgrowth of SCG neurons. Dissociated neurons were microporated 
with respective plasmids together with dsRed, plated and imaged 30 
hours later. The longest neurite of each neuron was traced and 
quantified with OpenLab (Fig. 7A). A representative composite image 
of all traced neurites within a single well was also included in the 
paper. 
 
Figure 7: Neurite traces of SCG neurons are shown in panel A. Red 
squares in panel B represent the cell soma of neurons shown in panel A. A 
representative composite image of all traces within a well is shown in panel 
B, note that both panels are different in scale.  
 
 
GABAergic neurite outgrowth of MGE neurons 
In paper III, we quantified GABAergic neurite outgrowth of neurons 
isolated from the medial ganglionic eminence (MGE). Cells were 
dissociated and incubated in their respective treatment conditions for 
48 hours before fixation, staining with anti-GABA antibodies and 
counterstained with DAPI. Pictures were taken with an Axiovert 200M 
inverted microscope using OpenLab. Neurite outgrowth counts were 
performed using the ImageJ software (NIH) on the GABAergic staining 
micrographs, setting cell perimeter threshold above 18000 and cell 
circularity below 0.5. These parameters designate a differentiated 
GABAergic bearing neurites to be longer than thrice the cell body 
diameter and excluding undifferentiated circular cells (Fig. 8). 
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Figure 8: GABAergic neurite outgrowth counts. GABAergic 
immunostainings are depicted in panel A. Cell perimeter threshold 
measurements using ImageJ are shown in panel B. The table illustrates 
the value obtained for cell perimeter and area. Note that cell number 9 (as 
indicated by ! in panel B) has extended neurites meeting neurite 
outgrowth threshold requirements, whereas cell number 14 (as identified 
by ") does not. Not all cells presented in the table are visible in panel A. 
 
NEURONAL MIGRATION 
In paper III, we analyzed the migration of cultured MGE, LGE and CGE 
GABAergic neurons. Freshly dissected tissue was dissociated and 
neurons were subsequently plated on a pre-coated PDL filter of a 
Boyden ChemoTx (Neuroprobe) chamber with a 5 #m pore size in a 
96-well format. Dissociated cells were resuspended and plated in the 
top chamber in a 50 #L drop as shown (Fig. 9, panel A). Cell migration 
was induced by adding growth factors or blocking antibodies in the 
lower compartment of the chamber. Cultures were incubated for 48 
hours, after which the cells remaining on the top of the filter were 
gently scrapped away with a cotton tip. The filters were then fixed in 
4% PFA and stained with DAPI. The lower side of the filters was 
imaged with an Axiovert 200M inverted fluorescence microscope 
(Zeiss) in the DAPI channel and quantified using the ImageJ software 
(NIH) (Fig 9B). 
 
Figure 9: A representative Boyden chamber used in the study is 
shown in panel A. Cell migration counts were performed on 
DAPI counterstainings of the filter depicted in panel B. 
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RESULTS AND DISCUSSION 
 
PAPER I 
 
Upon activation, the RET tyrosine kinase receptor undergoes 
autophosphorylation of intracellular tyrosine residues, which then serve 
as docking sites for downstream signaling effectors carrying Src 
homology (SH2) or phosphotyrosine-binding domains (PTB). Previous 
studies have indicated that at least 14 of the 18 tyrosine residues 
present in the intracellular region of RET can become phosphorylated. 
Of the remaining residues, only four have actually been shown to 
directly bind to a downstream effector in response to GDNF. The 
function of the majority of phosphorylated tyrosine residues in RET, 
including Tyr687, remains unknown. Tyr687 is located in the 
juxtamembrane region of the RET receptor, a domain known to exhibit 
regulatory functions in other catalytic receptors; signifying that Tyr687 
may be important for RET activation or for its downstream effects. 
 
In the first paper of this thesis, we evaluated the role of the 
juxtamembrane tyrosine residue Y687 of RET in GDNF-mediated 
signaling. Primarily, we aimed to identify the novel adaptor protein 
binding this phosphorylated tyrosine residue and subsequently, to 
understand the biological significance of this interaction. To achieve this, 
we prepared a T7 phage display cDNA library using differentiated PC12 
cells. For the screening of the library, we employed as bait a synthetic 
phosphopeptide derived from human RET encompassing phospho-
Y687 and flanked with 10 amino acid residues. The screen retrieved a 
phage clone encoding the N-terminal SH2 domain of the protein tyrosine 
phosphatase SHP2. We further showed that this phage clone was 
bound to the phospho-Y687 bait and was not bound to baits 
encompassing other RET phospho-Tyr residues. This result therefore 
argued for a direct interaction between RET and SHP2. In contrast, 
SHP2 has been shown to bind indirectly to RET at tyrosine residue 
Y1062 with the help of Gab2/Grb2 (Fig. 5) (Besset 2000). Noticeably, 
the SHP2 immunoreceptor tyrosine-based inhibitor motif (ITIM) includes 
a valine residue at the -2 position (I/V/L/S-x-pY-x-x-L/V), which is 
reminiscent of the RET target sequence VSpY687SSS (Songyang 1993, 
Liu 2006). We further showed that in the mammalian COS cell line, full 
length SHP2 requires the phosphorylation of Y687 to be bound to RET 
in a peptide pulldown assay using agarose beads coated with either the 
phosphorylated or the non-phosphorylated peptides used as baits. 
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Next, we analyzed the SHP2 binding determinants in RET using site-
directed mutagenesis of selected residues. Endogenous SHP2 was 
immunoprecipated in COS cells transfected with plasmids expressing 
the constitutively active form of RET, carrying the C634R mutation found 
in MEN2A patients. Both MEN2A-RET 51 and 9 isoforms were pulled 
down to similar levels with SHP2. In this background, we showed that 
the mutation of the tyrosine 687 into a phenylalanine (hereafter termed 
Y687F) failed to recover any RET protein in the SHP2 
immunoprecipitates; thereby validating Y687 as novel site for SHP2 
binding. Unexpectedly, mutation of tyrosine 1062 into a phenylalanine 
also abrogated the RET/SHP2 interaction, even though Y1062 is known 
to be a binding site for the multi-adaptor scaffolding complex 
Gab2/Grb2/SHP2 through Shc (Besset 2000). These results suggested 
that SHP2 might not be recruited to these two sites independently. 
Instead SHP2 may be forming a single signaling complex and binding 
both sites at the same time (Fig. 10); thus acting as a regulatory 
complex for RET signaling output.  
 
 
 
Figure 10: Theoretical schematic of SHP2 recruitment to both tyrosine 687 
and 1062, illustrating SH2-domain interactions with their respective 
phosphorylated tyrosine targets. Note the dimeric SHP2 molecule interacting 
with two phospho-Tyr targets simultaneously. 
 
To further investigate this hypothesis, we analyzed the influence of the 
Y687F mutation on the multi-adaptor assembly site Tyr1062. If SHP2 
were to be part of a multi-adaptor scaffolding complex binding directly to 
Y687 and indirectly to Y1062, then Shc or Gab2 immunoprecipitation 
studies would not only reveal intact levels of either protein binding to 
RET in the Y687F mutant compared to the wild-type, but also lower 
levels of SHP2. Indeed, association of SHP2 with Shc and Gab2 was 
diminished in the mutant, whereas RET levels were unaffected by the 
mutation. This data strongly argues that Tyr687 is necessary for SHP2 
recruitment to Y1062, and regulates multi-adaptor complex assembly. 
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While mapping the SHP2 binding determinants in RET, we found that 
the mutation of the serine residue S696 into an alanine strongly 
potentiated the binding of SHP2 to RET. This serine residue was shown 
to have an epistatic interaction with Y687 in lamellipodia formation of 
SK-N-MC cells (Fakuda 2002). When inserted into the Y687F mutant, 
the S696A mutation displayed a total loss of binding to SHP2 - arguing 
for a direct interaction between these two phosphorylation sites of RET. 
We further showed that forskolin treatment, an activator of adenylate 
cyclase, impaired SHP2 binding to RET upon GDNF stimulation in the 
MN1 cell line where both molecules are endogenously expressed. 
Forskolin has been shown to induce the phosphorylation of S696 of 
RET through PKA (Fakuda 2002). From these experiments, we 
concluded that the phosphorylation of serine 696 negatively regulates 
the binding of SHP2 to tyrosine 687 in RET. Unfortunately, the 
juxtamembrane was not included in the crystallized structure of the RET 
intracellular domain as recently published; however we advocate for a 
close proximity between S696 and Y687 with a possible reciprocal 
interference when phosphorylated (Knowles 2006).  
 
To understand the role of RET Y687 in GDNF-mediated signaling, we 
generated clonal fibroblast cell lines stably expressing either wild-type or 
the RET Y687F mutant. Although we found no major changes in the 
phosphorylation levels of RET, the Akt pathway - a downstream 
pathway of RET and PKA - was however strongly reduced in the mutant 
and never reached the levels of wild-type RET. Other downstream 
pathways such as Erk, Jnk, and Src were unaffected by the mutation, 
suggesting that RET signaling through Y687 may have a role in Akt-
mediated biological events such as cell differentiation and survival. 
Consequently, we examined the role of mutation Y687F in neuronal 
differentiation of PC12 cells. We found a major reduction of RET-
mediated neuronal differentiation in the Y687F mutant using the RET 
MEN2A background, after both 3 and 6 days of differentiation induction. 
We confirmed this result by employing GDNF-mediated differentiation 
instead of the constitutively active receptor. In accordance with our 
earlier data, inferring a negative role of PKA activity in SHP2 binding to 
RET, we observed that pre-treatment of PC12 cells with forskolin 
significantly reduced neuronal differentiation mediated by GDNF in the 
RET wild-type construct but not in either the Y687F mutant or the S696A 
mutant. 
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Finally, we evaluated the physiological role of tyrosine 687 in primary 
cultures of sympathetic neurons. Although SCG neurons endogenously 
express RET and GFR!1, we microporated the constitutively active 
form of RET to bypass the need of a ligand that would activate the 
endogenous receptors. We found that the Y687F mutation in both RET 
isoforms significantly reduced neurite outgrowth at DIV1, in agreement 
with our results obtained in PC12 cells. Since the Akt pathway is a 
mediator of neuronal survival, we expected to observe an increase in 
cell death of neurons expressing the RET mutant. We therefore set up a 
neuronal survival assay, in which SCG neurons were left to survive 
solely on the expression of the microporated constitutively active RET 
construct. SCG neurons were first microporated with the different RET 
constructs, incubated with minimal amounts of NGF for one night for cell 
recovery, and then cultured in !-NGF blocking antibody for a couple of 
days. From DIV3 on, we found that neurons expressing RET9 M2A 
Y687F exhibited axonal degeneration followed by cell soma collapse 
and were unable to sustain neuronal survival. Subsequent analysis with 
TUNEL staining confirmed that these neurons were apoptotic. 
 
Taken together, our results have identified SHP2 to be the first effector 
protein to bind to the phosphorylated tyrosine 687 of RET. Our evidence 
assigns a central role for Tyr687 in GDNF neurotrophic outputs and 
substantiates the evidence that its juxtramembrane location serves as a 
critical spatial integrator for the regulation of both RET and PKA 
signaling. 
 
 
 
PAPER II 
 
Patients with medullary thyroid carcinoma (MTC) and type 2A multiple 
endocrine neoplasia (MEN2A) contain cysteine residue mutations in the 
extracellular juxtamembrane region of RET. These mutations cause the 
formation of covalent receptor dimers linked by intermolecular disulfide 
bonds between unpaired cysteines, followed by oncogenic activation of 
the RET kinase. The close proximity to the plasma membrane of the 
affected cysteine residues prompted us to investigate the possible role 
of the RET transmembrane domain (RET-TM) in receptor-receptor 
interactions underlying dimer formation.  
 
In the second published article, we determined precisely how the RET-
TM engages in homo-dimer formation by unpaired cysteine residues in 
the context of mutations found in MEN2A and MTC patients. Receptor 
tyrosine kinases, such as RET, have a single-pass transmembrane 
domain that is thought to stabilize ligand-induced dimerization and to 
  20 
maintain receptors in close proximity in the plasma membrane. Gain of 
function Ret mutations typically found in human diseases involve 
cysteine residues in close proximity with the extracellular 
transmembrane of RET. MEN2A and MTC patients carry such 
mutations in juxtamembrane cysteine residues. Although the cyteine-
rich domain (CRD) of RET spans over 120 residues, most MEN2A and 
MTC mutations are found within the 25 residues of the plasma 
membrane, prompting us to examine the role of the transmembrane 
domain in self-association and oncogenic activation (Fig. 11).  
 
 
 
Figure 11: Schematic highlighting amino acid 
amino acid residues within the RET 
transmembrane (TM) domain that self-
associate upon oncogenic activation in the 
the MEN2A syndrome. 87% of MEN2A patients 
patients carry a mutation in cysteine 634 
634 (Cuccuru, 2004). 
 
 
 
To study the propensity of the RET-TM to self-associate we used the 
reporter ToxCAT system, which allowed us to quantify the efficiency of 
TM-TM interactions in a biological membrane. This reporter is based on 
the capacity of the ToxR transcriptional activator of the Vibrio Cholerae 
pathogen to bind to the cholera toxin (ctx) gene promoter only in 
dimerized form. Therefore, we fused the RET-TM (amino acids R635 to 
F657) to ToxR and the maltose-binding protein (MBP) for precise 
delivery to the Escherichia coli inner membrane. The fusion construct 
ToxR-RET-TM-MBP will then form dimers in the cytosol proportional to 
the oligomerization ability of the RET-TM domain. Following the binding 
of dimerized ToxR-RET-TM-MBP to the ctx DNA-binding element, the 
chloramphenicol transferase (cat) gene reporter was activated and 
consequent production of the CAT protein was quantified by ELISA. 
Indeed, the RET-TM showed a strong propensity to self-associate as the 
levels were comparable to other reported dimeric transmembrane 
receptors such as the ErbB family of receptors (Mendrola 2002). We 
then used a mutagenesis approach to find the self-association 
determinants of the RET-TM. By focusing our analysis on conserved 
serine and arginine residues in the RET-TM, we found the RET S649A 
and A641R mutants to have respectively a 50% and 80% loss of self-
association measured by CAT-ELISA compared to the wild-type.  
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Interestingly, a rare case of the double mutation A639G/A641R in exon 
11 was found in a tumor from a patient with sporadic MTC (Kalinin 
2002). This double missense mutation involves three nucleotide 
substitutions in the first and last residues of a triad of alanines. Yet the 
mechanism of how these residue substitutions disrupt RET-TM activity 
remained poorly understood. Thus, we included the A639G mutation 
into the wild-type fusion construct and into our A641R mutant. The 
A639G mutation marginally reduced RET-TM self-association. However 
when A639G was inserted together with A641R, the double mutant was 
not different from A641R alone as it displayed the same 80% reduction 
of relative self-association compared to the wild-type. To determine if 
the double mutations impaired RET function, we generated two clonal 
fibroblast cell lines stably expressing either the wild-type or the mutant 
construct. The double mutant did not display any phenotypic change 
when compared to the RET wild-type following GDNF stimulation. Both 
constructs were expressed at similar levels and the mutant did not 
display any impairment in expression of the mature form of RET. 
However, low basal RET activity was found in the double mutant 
through Western blot analysis using a phospho-specific antibody. Even 
though the A639G/A641R mutations showed detrimental effects on 
RET-TM self-association, the lack of spontaneous RET activity did not 
support a causative role for these mutations in MTC tumor formation. 
 
From this, we concluded that the two arginines A639 and A641 are 
crucial for RET dimerizing activity but do not promote an increase in 
RET basal activity. Nevertheless, it remains possible that these two 
arginines can stabilize RET homodimerization in a constitutively active 
setting such as the oncogenic RET C634R mutation found in MEN2A 
and FMTC patients. Hence, we analyzed dimer formation mediated by 
the C634R mutation in fibroblasts transfected with construct carrying or 
not the double arginine mutation. When running RET immuno-
precipitates on a non-reducing SDS-PAGE, we observed RET dimers in 
the C634R mutant when probing the membrane with a RET-specific 
antibody. However, the triple mutant C634R/A639G/A641R showed a 
statistically significant 47% reduction in dimer formation. Besides,  the 
transforming activity of the triple RET mutant was reduced to 
background levels in foci formation of fibroblasts plated in soft agar.  
 
Taken together, our results highlight the importance of TM-TM 
interactions in the self-association of RET by the MEN2A oncogenic 
activation. Both residues that we found to disrupt the self-association of 
RET are aligned on the same surface of a membrane-spanning alpha-
helix. With respect to the Ret gain of function mutation, our results bring 
a novel insight into the crucial role this transmembrane domain plays in 
the conformational stabilization of oncogenic homodimers. 
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PAPER III  
 
In humans, several psychiatric disorders have been correlated with 
cortical inhibitory interneuron malfunction including epilepsy, 
schizophrenia, and autism (Cossart 2005, Levitt, 2005; Rubenstein 
2003). Therefore, current research has focused its attention on 
understanding the signaling mechanisms that control the development 
of cortical GABAergic interneurons. GDNF is known to promote the 
differentiation and migration of MGE-derived GABAergic neuronal 
precursors (Pozas 2005). These functions have been shown to be 
dependent on the GPI-anchored receptor GFR!1, but are independent 
of the two known transmembrane receptor partners RET and NCAM. 
Since neither RET nor NCAM are required for the effects of GDNF on 
GABAergic interneuron migration and differentiation, then GFR!1 must 
somehow be able to either mediate GDNF signaling on its own or 
GFR!1 may partner with other transmembrane effectors expressed on 
these cells. Thus, the aim of the last paper was to elucidate the role of 
GDNF and GFR!1 signaling in GABAergic differentiation and migration 
of cortical interneuron precursors of the medial ganglionic eminence.  
 
First, we evaluated if soluble GFR!1 would be sufficient to promote 
neurite outgrowth of GABAergic positive MGE neurons. To test the 
effect of soluble GFR!1, we used a purified chimeric protein of the 
GFR!1 ectodomain (excluding the GPI-anchoring sequences) fused to 
the Fc domain of a human immunoglobulin (GFR!1-Fc). Indeed, we 
found that soluble GFR!1-Fc promoted the GABAergic neurite 
outgrowth of these cells and that GDNF further potentiated these 
effects. However, when both GDNF and GFR!1-Fc were combined the 
effects were not strictly additive. This result alluded to the likelihood that 
the same cell population was responding to either treatment.  
 
Since GDNF was reported to promote the tangential migration of 
GABAergic interneurons to the cortex, we tested both GDNF and 
GFR!1-Fc in a Boyden chamber assay to assess cell migration. In this 
system, dissociated cells are seeded on the top chamber and left to 
migrate through the pores towards the lower compartment where 
substances to be tested are presented. Both GDNF and GFR!1-Fc 
promoted cell migration measured after 48 hours. However, dissociated 
CGE and LGE neurons failed to migrate into the lower compartment 
when incubated with GDNF. This suggested that GDNF acts specifically 
on interneuron precursors from the MGE, which expresses GFR!1, but 
does not act on interneuron precursors of the LGE and CGE, as no 
GFR!1 expression is observed in these eminences at E12.5 in mice.  
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After showing that both GDNF and soluble GFR!1 induce GABAergic 
neurite outgrowth and migration of MGE neurons, we next verified if the 
biological effects of exogenous GFR!1-Fc were still dependent on 
GDNF or were independent of its known ligand. Since both GDNF and 
GFR!1 are expressed in the MGE at E12.5, we anticipated a loss of 
neurite outgrowth by GFR!1-Fc if endogenous GDNF was required for 
mediating this effect. Although GDNF mediated both neurite outgrowth 
and cell migration at similar levels between both wild-type and Gdnf -/- 
neurons, soluble GFR!1 indeed failed to induce any biological effect in 
knock-out neurons. Interestingly, these detrimental effects could be 
rescued when GDNF and GFR!1-Fc were applied concurrently. These 
results demonstrate that endogenous GDNF production is required for 
soluble GFR!1-Fc to mediate both GABAergic neurite outgrowth and 
migration of MGE neurons.  
 
We further evaluated if soluble GFR!1 could act in a non-cell 
autonomous fashion and treated Gfra1-/- neurons with GFR!1-Fc. 
GDNF did not promote any differentiation or migration in primary MGE 
neurons from Gfra1 knock-out embryos, confirming GFR!1 as a 
receptor of GDNF in these cells. However, soluble GFR!1 was sufficient 
to rescue these knock-out neurons in both GABAergic outgrowth and 
cell migration to similar levels observed in wild-type cells. Additionally, 
when both GDNF and GFR!1-Fc were added together, Gfra1 -/- neurons 
differentiated and migrated to a similar degree as wild-type cells. These 
compelling observations can only be explained by the existence of a 
novel transmembrane signaling partner for the GDNF/GFR!1 complex 
in MGE GABAergic neurons. (Fig. 12). 
 
 
 
Figure 12: Illustration 
depicting the probable 
interaction between the 
GDNF/GR!1 signaling 
complex and the novel 
transmembrane receptor 
which mediates 
GABAergic neurite 
outgrowth and cell 
migration in MGE 
neurons. 
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To investigate potential receptor candidates, we analyzed if ErbB4 could 
mediate GDNF/GFR!1 signaling activities, since this Neuregulin-1 
receptor is known to mediate the tangential migration of GABAergic 
MGE neurons (Flames 2004). To these means, we employed a 
biochemical approach and transiently stimulated wild-type MGE cultures 
with GDNF or Neuregulin-1. Although Neuregulin-1 induced a robust 
increase of the phosphorylation state of ErbB4 observed by Western 
blot, GDNF did not induce any phosphorylation of the receptor above 
background levels. This indicated that GDNF does not signal via ErbB4. 
When incubating MGE neurons with the specific pharmacological ErbB4 
inhibitor AG1478, we did not observe any GABAergic differentiation 
induced by the inhibitor alone. Moreover, when added together with 
GDNF, the inhibitor failed to inhibit the differentiation mediated by 
GDNF. Similar results were obtained with the Boyden chamber 
migration assay, thereby supporting the evidence that ErB4 is not a 
receptor for GDNF in MGE neurons. 
 
We then selected another receptor candidate, the HGF receptor MET, 
also known to mediate the tangential of MGE neurons into the cortex 
(Powell 2001). With the same rationale, we transiently stimulated MGE 
cultures with GDNF or HGF and analyzed the phosphorylation levels of 
the MET receptor. Although HGF induced a rapid increase of MET 
phosphorylation detected by a phospho-MET antibody in a Western blot, 
GDNF did not phosphorylate MET above background levels. 
Interestingly, the downstream pathway Erk was stimulated by both 
ligands, which confirmed previous evidence that GDNF activities are 
mediated through the ERK pathway (Pozas 2005). To test if MET was 
involved in GDNF-induced neurite outgrowth in MGE cells, we 
stimulated MGE cultures with GDNF in the presence or absence of the 
specific pharmacological MET kinase inhibitor SU11274. To our 
surprise, SU11274 induced GABAergic neurite outgrowth on its own and 
at comparable levels to GDNF. Interestingly, at the concentration of 1µM 
SU11274 blocked the activation of the Erk pathway, indicating that 
GABAergic neurite outgrowth is independent of the activation of the Erk 
pathway. When both GDNF and SU11274 were added together, the 
effects on neurite outgrowth were additive. To eliminate any undesired 
off-target effects of this inhibitor, we tested neurite outgrowth with 
another MET inhibitor PHA665752. Our previous evidence was 
confirmed as PHA665752 did induce GABAergic neurite outgrowth by 
itself. Taken together, we concluded that ErB4 and MET are not the 
transmembrane receptors mediating GDNF activities in MGE neurons. 
Instead, the inhibition of MET signaling unexpectedly promoted 
GABAergic neurite outgrowth in these cells. 
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Since the MET inhibitor SU11274 promoted neurite outgrowth by itself, 
we then decided to further investigate the role of MET signaling 
inhibition in MGE neurons using an antibody blocking HGF signaling. 
We chose this approach because it would eliminate the possibility of 
unspecific pharmacological inhibition of other kinases than MET. 
Although HGF did not promote any neurite outgrowth, the !#HGF 
blocking antibody induced robust GABAergic neurite outgrowth to a 
higher level than GDNF. When GDNF and !-HGF were added together, 
the effect on neurite outgrowth was additive; similar to the effect 
observed when GDNF and SU11274 were added together. Interestingly, 
HGF did not reduce the effect of GDNF when both were added together. 
In Boyden chambers, !-HGF proved to be more potent than GDNF in 
promoting cell migration, even with a synergistic induction when both 
were added simultaneously.  
 
These results prompted us to further analyze if the biological outputs 
observed in MET signaling inhibition were dependent on GDNF 
signaling. Therefore, we utilized a !-GDNF blocking antibody to inhibit 
all GDNF-mediated signaling in these neurons. As control experiments, 
we first tested the specificity of the antibody in inhibiting GDNF activities 
in neurite outgrowth. We also evaluated this GDNF inhibition in 
conjunction with BDNF, another ligand promoting neurite outgrowth in 
MGE neurons (Pozas 2005), and found that !-GDNF failed to inhibit the 
GABAergic neurite outgrowth mediated by BDNF. Interestingly, when 
added together with !-GDNF, !-HGF also failed to induce any 
GABAergic neurite outgrowth above background levels. These results 
argue that !-HGF is dependent on endogenous GDNF signaling to 
mediate GABAergic neurite outgrowth of MGE neurons. 
 
To verify if !-HGF requires endogenous GDNF signaling to mediate 
neurite outgrowth, we utilized an in vitro approach and cultured knock-
out neurons. Therefore, we assessed GABAergic neurite outgrowth and 
cell migration in cultured MGE neurons derived from Gfra1-/- embryos 
and treated them with !-HGF. Both biological outputs showed an 
impairment of !-HGF to exert its activity in Gfra1-/- neurons, confirming 
that !-HGF is dependent on endogenous GDNF/GFR!1 signaling. 
Moreover, these results imply that HGF signaling through MET may 
restrict GDNF activities in these neurons since MET is broadly 
expressed in the MGE at E12.5. 
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To test this hypothesis, we used MGE cultures derived from MET 
mutant mice carrying a double (D) point mutation of two tyrosine 
residues into phenylalanine in the intracellular domain the MET receptor. 
MET D/D embryos display the same phenotype as MET null mutants and 
are incapable of MET signaling induction both in vitro and in vivo (Maina 
1996). We observed an enhanced response to GDNF in MET D/D 
neurons both in GABAergic neurite outgrowth and migration. 
Conclusively, these neurons exhibited a statistically significant increase 
in GABAergic neurite differentiation and cell migration even in untreated 
conditions.  
 
In order to understand how MET signaling could negatively regulate 
GDNF signaling, we investigated the expression of both MET and 
GFR!1 in the MGE. Both receptors were expressed in the postmitotic 
mantle zone of the MGE. While MET was more broadly expressed than 
GFR!1, some cells did exhibit co-expression of both receptors. Next, we 
performed quantitative real-time PCR of RNA extracted from wild-type 
MGE neurons that were treated for 48 hours and measured Gfra1 
mRNA expression. Surprisingly, we found that dissociated MGE cells 
cultured for two days in control conditions displayed significantly 
reduced levels of Gfra1 mRNA compared to freshly dissected E12.5 
MGE tissue. Incubation of these cells with GDNF restored Gfra1 mRNA 
expression in DIV2 MGE cultures to similar levels displayed by the 
freshly dissected E12.5 MGE tissue. GFR!1-Fc also had an effect on 
Gfra1 mRNA expression but was lower than GDNF. We further showed 
that the !-HGF blocking antibody and the SU11274 Met inhibitor 
increased the level of Gfra1 mRNA in cultured MGE cells to a similar 
extent as GDNF. As the trophic effects of HGF/Met inhibition were 
mediated by endogenous GDNF signaling, we tested if the effects 
observed on Gfra1 mRNA expression were also dependent on GDNF 
and therefore combined !-HGF and !-GDNF treatments to assess the 
levels of Gfra1 mRNA expression. Unlike its effect on neurite outgrowth, 
!-GDNF did not impair the ability of !-HGF to increase Gfra1 mRNA 
levels in our MGE cultures, suggesting that endogenous HGF/MET 
represses Gfra1 mRNA expression in MGE cells. 
 
Together, these results conclude that endogenous HGF signaling 
through MET restricts the effects of GDNF/GFR!1 signaling in both the 
differentiation and migration of GABAergic MGE neurons. This negative 
regulation of GDNF signaling by MET may play a crucial role in early 
developmental diversification of GABAergic interneuron subtypes in the 
MGE. 
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CONCLUSION 
 
When GDNF was discovered seventeen years ago, it was merely 
acknowledged for its capacity to promote the survival of embryonic 
midbrain dopaminergic neurons. Extensive work from recent years has 
now appropriately recognized the diverse biological influence of this 
growth factor in nervous system development and function. This thesis 
has contributed to our understanding of the physiological and cellular 
events mediated by GDNF and its receptors by offering the following 
new insights: 
 
• Discovery of the first adaptor protein to bind phospho-Tyr687 of RET. 
• Identification of the first direct binding site for SHP2 in RET. 
• Promotion of sympathetic neuron survival and neurite outgrowth mediated 
by SHP2 binding to RET Y687. 
• Elucidation of the self-association determinants of the RET transmembrane 
domain. 
• Description of how the RET-TM self-associates and stabilizes receptor-
receptor interactions in constitutive dimers formed by the C634R mutation 
found in MEN2A and MTC patients.  
• Localization of crucial residues for RET TM-TM interactions assuming a !-
helix transmembrane conformation. 
• Demonstration of soluble GFR!1’s ability to promote GABAergic neurite 
outgrowth and migration in primary MGE neurons. 
• Justification for the presence of a novel transmembrane receptor expressed 
in the MGE for the GDNF/ GFR!1 signaling complex 
• Validation of MET signaling restriction on GDNF activities in MGE 
neurons.  
 
Our understanding of how neurons precisely integrate and interpret 
GDNF signaling remains unclear. Further investigation is necessary to 
clarify the effects these signals have on cellular function. Specifically, it 
would be significant to identify the function of other phosphorylated 
tyrosine residues in RET and in other RTKs. This information would 
allow for a better application of RET-mediated signaling in a clinical 
context. With respect to GDNF signaling, it will be important to identify 
the novel receptor partner of the GDNF/GFR!1 complex and evaluate 
its interaction with MET signaling. A thorough understanding of the 
molecular mechanisms by which GDNF functions in different neuronal 
population will be essential in elucidating its contribution to nervous 
system development and exploiting its therapeutic potential.   
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EPILOGUE 
 
Seventeen years have passed since scientists initially embarked on 
the hopeful quest to make GDNF a therapeutic agent for Parkinson’s 
disease patients. Since then our knowledge of GDNF’s mechanisms of 
action has staggeringly increased; while the technological 
developments for GDNF delivery into the human brain have 
unfortunately faltered. A recent clinical trial by Ceregene, employing an 
adeno-associated virus encoding the Neurturin gene, failed to show 
any symptomatic improvement in 58 PD patients even one year after 
the virus injection. The first post-mortem brains of this study confirmed 
that only 15% of the putamen was expressing the recombinant protein. 
Once again, the therapeutic agent did not reach the target tissue 
accurately (Vastag 2010). However, GDNF demonstrated clinical 
improvement for PD patients in a singular clinical trial, where 
subsequent post-mortem brain analysis showed massive sprouting in 
neuronal fibers of the putamen - the site where the catheter had been 
surgically inserted (Gill 2003, Love 2005).  
Scientifically much work remains before we will clearly understand the 
dynamic capabilities of GDNF and be able to apply them in a clinical 
setting. Nevertheless, my hopes have not faltered, as I believe there is 
a future for GDNF as therapeutic agent, even beyond Parkinson’s 
disease. GDNF has yielded both neuroprotective and regenerative 
results in animal models of spinal cord injury, nerve trauma, ALS, and 
stroke. These prospective hopes now rely on the design of newly 
engineered technologies for drug delivery, as well as, on the will of 
scientists to bring the findings of their research endeavors from the 
bench to the bedside where they deservingly belong… 
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